chr10-87933127-A-G
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM2PM6PP2PM1PS3
This summary comes from the ClinGen Evidence Repository: PTEN c.368A>G (p.His123Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29706350)PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel.PM2: Absent in large sequenced populations PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10234502)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. LINK:https://erepo.genome.network/evrepo/ui/classification/CA000418/MONDO:0017623/003
Frequency
Consequence
NM_000314.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTEN | NM_000314.8 | c.368A>G | p.His123Arg | missense_variant | 5/9 | ENST00000371953.8 | NP_000305.3 | |
PTEN | NM_001304717.5 | c.887A>G | p.His296Arg | missense_variant | 6/10 | NP_001291646.4 | ||
PTEN | NM_001304718.2 | c.-383A>G | 5_prime_UTR_variant | 4/9 | NP_001291647.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTEN | ENST00000371953.8 | c.368A>G | p.His123Arg | missense_variant | 5/9 | 1 | NM_000314.8 | ENSP00000361021.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
PTEN hamartoma tumor syndrome Pathogenic:2
Pathogenic, reviewed by expert panel | curation | Clingen PTEN Variant Curation Expert Panel, Clingen | Jun 18, 2020 | PTEN c.368A>G (p.His123Arg) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS3: Phosphatase activity <50% of wild type (PMID 29706350) PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel. PM2: Absent in large sequenced populations PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10234502) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 14, 2022 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.His123 amino acid residue in PTEN. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9256433, 10555148, 10772829, 16619501, 21828076; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects PTEN function (PMID: 29706350). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Not Available"). ClinVar contains an entry for this variant (Variation ID: 7816). This missense change has been observed in individuals with clinical features of PTEN-related conditions (PMID: 9259288, 10234502; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 123 of the PTEN protein (p.His123Arg). - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 28, 2017 | This variant is denoted PTEN c.368A>G at the cDNA level, p.His123Arg (H123R) at the protein level,and results in the change of a Histidine to an Arginine (CAC>CGC). This variant was found to occur de novo in apatient with Cowden syndrome (Nelen 1997, Nelen 1999). Additionally, other amino acid changes at the His123residue - PTEN His123Gln, His123Tyr, and His123Asp - have been reported in individuals with clinical historiesconsistent with PTEN Hamartoma Tumor syndrome and on functional interrogation demonstrated absent or decreasedphosphatase activity and inability to rescue or regulate cell growth (Myers 1997, Lee 1999, Bussaglia 2002, Rodriguez-Escudero 2011, Kersseboom 2011, Spinelli 2015, Hansen-Kiss 2017). PTEN His123Arg was not observed in largepopulation cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016). SinceHistidine and Arginine share similar properties, this is considered a conservative amino acid substitution. PTENHis123Arg occurs at a position that is conserved across species and is located in an ATP binding motif andphosphatase core domain (Lee 1999, Lobo 2009, Molinari 2014). In silico analyses predict that this variant is probablydamaging to protein structure and function. Based on currently available evidence, we consider this variant to bepathogenic - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Feb 15, 2021 | This variant has been reported in the published literature in an individual affected with Cowden syndrome and a malignancy in the thyroid gland (PMID: 9259288 (1997), 10234502 (1999)). In addition, a functional study using transformed yeast and analysis by logistic regression has described the variant as having reduced PTEN activity to truncation-like levels (PMID: 29706350 (2018), 32442409 (2020)). Based on the available information, this variant is classified as pathogenic. - |
PTEN-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 23, 2023 | The PTEN c.368A>G variant is predicted to result in the amino acid substitution p.His123Arg. This variant was reported in individuals with PTEN hamartoma tumor syndrome, including at least one de novo case (patient n40, Nelen et al. 1999. PubMed ID: 10234502; Wang et al. 2023. PubMed ID: 36453251). Functional studies showed that this variant impacts protein function (Table S1, Mighell et al. 2020. PubMed ID: 32442409). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Different nucleotide substitutions affecting the same amino acid (p.His123Asp and p.His123Tyr) have been reported in individuals with PTEN hamartoma tumor syndrome (Human Gene Mutation Database). The c.368A>G (p.His123Arg) variant is classified as pathogenic by ClinGen PTEN Variant Curation Expert Panel. This variant is interpreted as pathogenic. - |
Cowden syndrome 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 1997 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at